Vericel Corp. (VCEL) Trading 3% Higher
Vericel Corp. (NASDAQ:VCEL) shares traded up 3% during mid-day trading on Tuesday . The stock traded as high as $2.47 and last traded at $2.44, with a volume of 213,135 shares. The stock had previously closed at $2.37.
The stock has a 50-day moving average of $2.27 and a 200 day moving average of $2.84. The stock’s market cap is $50.80 million.
Vericel Corp. (NASDAQ:VCEL) last posted its quarterly earnings data on Monday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.05. The company earned $12.80 million during the quarter, compared to the consensus estimate of $15.05 million. Equities analysts expect that Vericel Corp. will post ($0.91) EPS for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/vericel-corp-vcel-trading-3-higher.html
A number of large investors have recently bought and sold shares of the company. State Street Corp bought a new position in shares of Vericel Corp. during the first quarter valued at $107,000. BlackRock Fund Advisors boosted its position in shares of Vericel Corp. by 21.7% in the second quarter. BlackRock Fund Advisors now owns 67,879 shares of the company’s stock valued at $153,000 after buying an additional 12,117 shares in the last quarter. A.R.T. Advisors LLC bought a new position in shares of Vericel Corp. during the second quarter valued at $248,000. Numeric Investors LLC bought a new position in shares of Vericel Corp. during the second quarter valued at $261,000. Finally, Goldman Sachs Group Inc. boosted its position in shares of Vericel Corp. by 180.8% in the first quarter. Goldman Sachs Group Inc. now owns 47,471 shares of the company’s stock valued at $278,000 after buying an additional 30,568 shares in the last quarter. Institutional investors own 45.44% of the company’s stock.
About Vericel Corp.
Vericel Corporation, formerly Aastrom Biosciences, Inc, is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment.
Receive News & Ratings for Vericel Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corp. and related companies with MarketBeat.com's FREE daily email newsletter.